Efficacy and Safety Of AGE ZERO™ EXOSOMES To Treat Men and Women With Androgenetic Alopecia
ConditionAndrogenetic Alopecia
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorLevit Dermatology
About this trial
The purpose of this study is to determine whether Wharton's Jelly mesenchymal stem cell-derived exosome microneedling on the scalp is an effective treatment for Androgenetic Alopecia (pattern hair loss).
Eligibility criteria
Qualifiers
Participant is experiencing hair loss and is diagnosed with Androgenetic Alopecia.
Disqualifiers
Patients cannot have taken any medications, therapies, or treatment modalities of any kind to treat hair loss in the last six months.
Patients cannot have open wounds, eczema, or psoriatic plaques on the treatment area of the scalp.
Patients who are undergoing or have undergone chemotherapy and or radiation therapy within the past 6 months
Patients with a history of an autoimmune bullous disorder (having auto-antibodies to Dsg-1 or Dsg-3)
Trial design
Treatments tested in this trial
- 5 billion exosomes and saline solution microneedling
- 50 billion exosomes and saline solution microneedling
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Levit Dermatology
Lead sponsor
ResilielleTM Age ZeroTM Exosomes
Collaborator
Dorisca Research Consulting, LLC
Collaborator
Source ClinicalTrials.gov